Remdesivir is a drug, not a vaccine, so its manufacturer, Gilead, can be sued. Some of the medical personnel who administered the drug reportedly nicknamed it “run, death is near.” From Dr. Joseph Mercola at childrenshealthdefense.org:
Story at a glance:
- The antiviral drug remdesivir, brand name Veklury, is approved for use against COVID-19 despite research showing it lacks effectiveness and can cause high rates of organ failure.
- John Beaudoin is calling for a criminal investigation into remdesivir, citing data that it may have killed 100,000 people in the U.S.
- Beaudoin received all the death certificates in Massachusetts from 2015 to 2022, finding 1,840 excess deaths from acute renal failure from Jan. 1, 2021, to Nov. 30, 2022, which he believes may be due to remdesivir.
- A study published in The Lancet found “no clinical benefit” from the use of remdesivir in hospitalized patients.
- The U.S. government pays hospitals a 20% upcharge on the entire hospital bill when remdesivir is used.
The U.S. Food and Drug Administration (FDA) authorized the experimental antiviral drug remdesivir, brand name Veklury, for emergency use against COVID-19 in May 2020.
By October 2020, it had received full approval. It remains a primary treatment for COVID-19 in hospitals, despite research showing it lacks effectiveness and can cause high rates of organ failure.
Gilead has a vested interest in making sure the world doesn’t hear about or use hydroxychloroquine. From Antonio R. Chaves at americanthinker.com:
s Gilead, the maker of Remdesivir, waging war on HCQ (hydroxychloroquine)? Attacks on the drug have been continuous ever since Dr. Didier Raoult used this quinine derivative to save the lives of COVID-19 patients last March. The first attempt to discredit HCQ was a hastily compiled Veterans’ Administration hospital system study last April. Notably, one of the study’s authors had in the past received numerous grants from Gilead, with one grant in 2018 totaling nearly a quarter of a million dollars.
After deep flaws in the V.A. study were exposed, Surgisphere came to the rescue in May with a “15,000 patient” megastudy allegedly compiled from hospitals all over the world. This strategy succeeded: following its publication in the Lancet and the NEJM, all outpatient use of HCQ was severely restricted in the U.S., Australia, and most of Europe.
When the Surgisphere scam was exposed, both articles were quietly retracted, and the editor-in-chief of the Lancet tried to wash his hands of this embarrassing incident by denouncing Surgisphere’s “monumental fraud.” However only a few days earlier, Lancet editors played a major role in persuading the WHO to suspend all trials for HCQ. Who put them up to it?
Say it isn’t so. Surely large corporations wouldn’t use the power of government to stifle a cheaper and more effective product. From Monica Showalter at americanthinker.com:
When President Trump brought up hydroxychloroquine as a promising potential treatment for COVID-19, a huge upsurge of negative political publicity followed from it. It was strange stuff, because up until then, the treatment, which had been safely used to treat malaria, lupus, and arthritis, had been seeing promising results for COVID-19, too. Yet the condemnations from all sides poured for weeks. It wasn’t just the political establishment blasting it; it seemed to be the medical establishment, too. That raises questions as to whether financial interests might be involved here.
It started with the press engaging in its customary contrarianism against Trump when he called the treatment “promising.” The logic was simple: If Trump liked it, then it had to be bad.
How’s this for a slanted headline and report from NPR, which ran on April 10?
COVID-19 Patients Given Unproven Drug In Texas Nursing Home In ‘Disconcerting’ Move